GGM Financials LLC Invests $233,000 in Merck & Co., Inc. (NYSE:MRK)

by · The Markets Daily

GGM Financials LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,055 shares of the company’s stock, valued at approximately $233,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its stake in Merck & Co., Inc. by 16.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 63,101 shares of the company’s stock worth $7,211,000 after purchasing an additional 8,985 shares during the last quarter. AMF Tjanstepension AB lifted its position in shares of Merck & Co., Inc. by 114.2% during the 3rd quarter. AMF Tjanstepension AB now owns 802,384 shares of the company’s stock worth $91,205,000 after buying an additional 427,831 shares during the last quarter. M&G Plc bought a new position in Merck & Co., Inc. in the first quarter valued at about $48,921,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its stake in Merck & Co., Inc. by 59.8% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 485,103 shares of the company’s stock worth $60,056,000 after acquiring an additional 181,520 shares in the last quarter. Finally, Latko Wealth Management Ltd. acquired a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at approximately $3,296,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.9 %

MRK opened at $100.72 on Thursday. Merck & Co., Inc. has a fifty-two week low of $98.60 and a fifty-two week high of $134.63. The firm has a market capitalization of $255.10 billion, a PE ratio of 21.12, a P/E/G ratio of 1.46 and a beta of 0.40. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.47 and a quick ratio of 1.22. The company’s 50-day moving average is $111.37 and its 200 day moving average is $120.33.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $1.50 by $0.07. The firm had revenue of $16.66 billion during the quarter, compared to the consensus estimate of $16.47 billion. Merck & Co., Inc. had a return on equity of 37.32% and a net margin of 19.23%. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.13 earnings per share. As a group, research analysts predict that Merck & Co., Inc. will post 7.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Truist Financial dropped their price objective on shares of Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th. BMO Capital Markets lowered their target price on Merck & Co., Inc. from $150.00 to $136.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Guggenheim reduced their price target on Merck & Co., Inc. from $137.00 to $130.00 and set a “buy” rating on the stock in a report on Wednesday. Citigroup decreased their price objective on Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating for the company in a report on Friday, October 25th. Finally, UBS Group dropped their price target on shares of Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday, October 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have issued a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.93.

View Our Latest Report on MRK

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also